Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ.
Pohl MA, et al. Among authors: ritz e.
J Am Soc Nephrol. 2005 Oct;16(10):3027-37. doi: 10.1681/ASN.2004110919. Epub 2005 Aug 24.
J Am Soc Nephrol. 2005.
PMID: 16120823
Clinical Trial.